GAITHERSBURG, MD–(Marketwire -05/16/12)- Cytomedix, Inc. (OTC.BB: CMXI) (the “Company”), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies for wound and tissue repair, announced that the independent Data Safety Monitoring Board (DSMB) reviewing the safety data from the ongoing RECOVER-Stroke trial has recommended that the Phase 2 trial of ALD-401, a unique and differentiated stem cell population derived from patients’ own bone marrow, can continue as designed. This determination follows a review of the clinical safety data on the first 10 patients that were treated post-acutely for ischemic stroke.

The double-blind, placebo-controlled trial of 100 patients is designed to assess the safety and efficacy of ALD-401 to improve clinical outcomes in patients with unilateral, cerebral ischemic stroke with an NIH stroke scale score of between 7 and 22 when administered between 13 and 19 days post the ischemic event. The primary endpoint of the study is safety and the secondary efficacy endpoint is neural function based on the modified Rankin Scale assessed at three months following treatment.

Currently being conducted at three clinical sites, the trial will now expand up to a total of approximately 15 U.S. clinical sites with this clearance by the DSMB. The study has gained Investigation Review Board (“IRB”) approval from a number of leading healthcare institutions under the guidance of key opinion leaders in the field of ischemic stroke. Additional DSMB reviews are scheduled at 30 and 60 patients per the clinical protocol.

Commenting on the clearance to continue the Phase 2 trial, Martin P. Rosendale, Chief Executive Officer, stated, “We are very encouraged by the decision of the DSMB to recommend the continuation of the RECOVER-Stroke trial and look forward to expanding this important trial to additional leading stroke clinical sites across the U.S. The only currently approved treatment options (tissue plasminogen activator (tPA) and mechanical retrievers) must be used within a very short time frame from the onset of the stroke. Consequently, less than 5% of stroke patients receive any approved treatments. ALD-401 is being delivered to patients suffering from the often devastating effects of ischemic stroke approximately two weeks following the stroke.

“Strokes remain one of the leading causes of long-term disability. With the majority of strokes occurring in patients 65 years and older, it is also a major financial burden for our healthcare system. Preclinical research with ALD-401 has shown improvements in motor function, in mitigation of the decrease in brain volume, the reversal of decline in stroke-induced cell viability, and improved blood flow in the brain. We are hopeful that ALD-401 will continue to demonstrate these regenerative activities in this trial and look forward to advancing its clinical development,” added Mr. Rosendale.

“We are grateful to our early investigators, which include the University of Texas Health Science Center at Houston, Duke University Medical Center, and the Los Angeles Brain and Spine Institute, for their support and guidance through the early enrollment of this trial. We also look forward to working with a number of premier academic and private health leaders as we expand the study. Importantly, we want to recognize the care and thoughtful guidance received from our independent DSMB,” commented James Hinson, M.D., Cytomedix’ Chief Medical Officer. “We just concluded an Investigator’s Meeting and were especially pleased and encouraged to see the underlying enthusiasm for this potential treatment option among leading clinicians in stroke treatment and research.”

About Stroke

According to the American Stroke Association, stroke is a disease that affects the arteries leading to and within the brain. It is the fourth leading cause of death and a leading cause of disability in the United States. A stroke occurs when a blood vessel that carries oxygen and nutrients to the brain is either blocked by a clot or bursts. When that happens, part of the brain cannot get the blood and oxygen it needs, so it starts to die. Strokes are typically classified into two major categories: ischemic and hemorrhagic. Approximately 800,000 patients in the United States suffer a stroke each year and approximately 87% of these strokes are ischemic.

About ALD-401

ALD-401 is the population of ALDHbr stem cells produced using Cytomedix’ proprietary technology to sort a specified quantity of bone marrow collected from the patient receiving the therapy. These adult stem cells express high levels of the enzyme ALDH, and preclinical research suggests that they may promote the repair of ischemic tissue damage. This is tissue damage caused by inadequate blood flow resulting from the obstruction of blood vessels supplying blood to the tissue. Investigators have completed preclinical research showed improvements in motor function, improvements in the slowing of decrease in brain volume, the reversal of decline in stroke-induced cell viability, and improved blood flow, or perfusion, in the brain.

Go here to read the rest:
Cytomedix Announces Expansion of Phase 2 Study to Treat Post-Acute Ischemic Stroke at Up to 15 U.S. Clinical Sites

Animal stem cell regenerative therapy is the newest service at the Animal Hospital of Tiffin.

“We are the official first site for the therapy in Ohio,” said veterinarian Bob McClung.

The technology uses an adult animal’s stem cells to heal itself.

Veterinarian Mike Brothers performed the surgery Monday on his dog, Tucker, a 2-year-old labrador retriever. It was the second surgery performed at the clinic.

Brothers said his dog’s joint problems are hereditary and he’s had problems since he was a puppy.

“What we’ve been able to do is slow down the arthritis,” Brothers said. The cause of the degeneration will continue, but the fatty tissue removed from the dog can be used for future treatments.

From a piece of fatty tissue of the size removed from Tucker, McClung estimated $3.2 billion stem cells were harvested.

Each injection uses about 90 million cells, so there will be enough of the material for future treatments.

“We have basically 2 billion cells to bank,” he said. “We use cryo-preservation.”

In the freezing process, the cells are gradually cooled to prevent damage and stored in liquid nitrogen at temperatures of minus 80 to minus 90 degrees Fahrenheit.

More:
Vet undertakes stem cell surgery

Kolkata, May 15:

Stem cell banking companies are looking at aggressive marketing initiatives to move into the mass market segment. Direct marketing to customers and reduction in price tag for storing umbilical cord blood are on the cards.

The umbilical cord blood and cord tissue are one of the richest sources of stem cells and have potential to treat over 75 serious ailments.

The average cost for storing these for a period of 21 years ranges between Rs 75,000 and Rs 90,000 in India.

According to Chennai-based Life Cell, high price points and lack of proper marketing have limited the penetration of cord blood banking in India. Affordability is the key factor in India.

Only when the prices come down will we see more customers opting for the service. We are working on it (bringing down prices), Mr Mayur Abhaya Srisrimal, Executive Director Life Cell, told Business Line.

Stem cell bankers have already rolled out easy finance options such as EMIs to make the services attractive. CordLife, for instance, offers EMI facility for 12-24 months.

This has helped boost our sales. We have been acquiring 350-400 clients each month, said Managing Director, Mr Meghnath Roy Chowdhury.

Finance, however, is not the only stumbling block. Cord blood bankers have, so far, been depending largely on hospital network for signing up clients. Bangalore-based Ms Deepa Shankar, who is expecting and is due for delivery in June, recently opted for Life Cell services through the hospital.

It’s not a sustainable approach. We need to get into direct marketing for pushing up volumes growth, Mr Srisrimal points out. To strike a cord with the would-be mothers, the company has roped in Lisa Ray as brand ambassador. Ms Ray was cured of multiple myeloma courtesy stem cell therapy.

Continued here:
Stem cell banking firms to deploy marketing initiatives to boost sales

Here is the original post:
Scientists Discover Marker to Identify, Attack Breast Cancer Stem Cells

CARLSBAD, Calif.–(BUSINESS WIRE)–

International Stem Cell Corporation (OTCBB: ISCO.OB – News) (www.internationalstemcell.com) today announced that several of its leading scientists will present experimental results from three of ISCOs pre-clinical therapeutic programs.

Firstly, the application of A9 dopaminergic neurons derived from human parthenogenetic stem cells (hpSC) for the treatment of Parkinsons disease. Demonstrating functional dopaminergic neurons in vivo represents an important milestone towards the goal of creating well characterized populations of cells that could be used to develop a treatment for Parkinsons.

Secondly, the differentiation of hpSC and embryonic stem cells into cornea-like constructs for use in transplantation therapy and the in vitro study of ocular drug absorption. There are approximately ten million people worldwide who are blind as a result of damage to their cornea. Generating human corneas from a pluripotent stem cell source should increase the likelihood that people will receive treatment in the future even in the absence of suitable tissue from eye banks.

Lastly, the in vivo and in vitro characterization of immature hepatocyte derived from hpSC. Such cells could be used to develop a treatment for individuals with a liver that has been damaged by disease or sufferers of genetic disorders that inhibit normal liver function. In both cases, implanting healthy hepatocyte cells could treat the underlying disease and prolong the life of the individual.

These results not only show the progress we have made in these important programs, but also demonstrate the broad application of human parthenogenetic stem cells in the development of treatments for incurable diseases, says Dr. Ruslan Semechkin, Vice President of Research and Development.

The presentations will take place at the 15th Annual Meeting of American Society of Gene and Cell Therapy, in Philadelphia at 3:30 p.m. on Thursday, May 17th.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com or follow us on Twitter @intlstemcell.

To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

More:
International Stem Cell Corporation Scientists to Present Pre-Clinical Research Results at American Society of Gene …

NAPLES, Fla.–(BUSINESS WIRE)–

Industrial Nanotech, Inc. (Pink Sheets:INTK), an emerging global leader in nanotechnology based energy saving and sustainable solutions announced today that the Company is opening a Corporate Sales Office in India with the next 4-6 weeks. Industrial Nanotech, Inc. has seen significantly increased demand in India for their Nansulate energy saving and protective coatings from OEM manufacturers as well as end manufacturing users to reduce energy costs. The company plans to establish an office first in Southern India, in or near Bangalore, with expansion to Northern India and Western India in the near future.

India has become an increasingly important country as their manufacturing sectors and economy as a whole continue to have a healthy growth rate, stated Francesca Crolley, VP of Business Development for Industrial Nanotech, Inc. We began a strategy this year focused on boosting our marketing and brand presence in India as an energy saving solution and it has returned significant results. These include multiple inquiries from manufacturers that want to use Nansulate coatings for insulation of their equipment for energy savings and surface temperature reduction, as well as a meeting with a leading OEM manufacturer of process cooling systems with 14 locations throughout India, and an international client base, that is interested in incorporating our technology into the process cooling systems they manufacture and sell. We have seen our marketing, which was focused on commercial and industrial, bring in sales and inquiries from multiple markets and at such a response level that it was obvious to us that setting up an Industrial Nanotech, Inc. office in India, staffed by a sales and technical support team which we hire and train, was the logical next step. The availability of a well educated workforce with an excellent work ethic presents a tremendous opportunity for the Company and will allow us to both accommodate factory visit requests from around the country with our own technical teams, as we do in the US, and the ability to more rapidly service and grow this vital market.

India’s economic growth is expected to remain robust in 2012 and 2013, despite likely headwind of double-dip recessions in Europe and the US, according to a United Nations’ annual economic report – World Economic Situation and Prospects 2012. The Indian economy is expected to grow between 7.7 per cent and 7.9 per cent this year, as per the report. India is the second most preferred destination for foreign investors, according to the report ‘Doing Business in India’ by Ernst & Young. The report explores India’s key sectors, investment climate, funding scenario, laws and regulations, to aid companies that are doing, or plan to do business in India.

About Nansulate

Nansulate is the Company’s patented product line of award winning, specialty coatings containing a nanotechnology based material and which are well-documented to provide the combined performance qualities of thermal insulation, corrosion prevention, resistance to mold growth, fire resistance, chemical resistance and lead encapsulation in an environmentally safe, water-based, coating formulation. The Nansulate Product Line includes industrial, residential, agricultural and solar thermal insulation coatings. Additional information about the Company and its products can be found at their websites, (www.inanotk.com) and (www.nansulate.com). Blog: www.nansulate.com/nanoblog, Twitter: www.twitter.com/NanoPioneer, Facebook: www.facebook.com/Nansulate.

About Industrial Nanotech Inc.

Industrial Nanotech Inc. is a global nanoscience solutions and research leader and member of the U.S. Green Building Council. The Company develops and commercializes new and innovative applications for sustainable nanotechnology which are sold worldwide.

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

Here is the original post:
Industrial Nanotech, Inc. Announces Expansion to India with Corporate Sales Office

A nanotechnology system that will allow sailors on Navy submarines to breathe easy has won Pacific Northwest National Laboratory a national award.

The 2012 Federal Laboratory Consortium Interagency Partnership Award was given to the Department of Energy national lab in Richland.

Researchers created a system that captures carbon dioxide directly from the air within a submarine to improve air quality, while providing a more environmentally friendly removal process.

The technology — self assembled monolayers on mesoporous supports or SAMMS — can be used to replace a system relied on for more than half a century by the U.S. Navy and many other countries.

The current system is a bulky, heavy, corrosive and malodorous liquid process that produces a significant amount of organic solvent waste, according to PNNL.

“This is a new application of a technology that was previously developed by PNNL to remove heavy metal contamination from ground and surface waters found at many DOE waste sites,” PNNL material scientist Glen Fryxell, one of the key inventors of the SAMMS technology, said in a statement.

The SAMMS materials can absorb large quantities of liquid and airborne contaminants without creating secondary waste and can be disposed of as nonhazardous waste.

The SAMMS technology is based on a new class of hybrid nanoporous materials that can rapidly capture contaminants such as carbon dioxide, mercury or arsenic directly from the atmosphere or liquid environments.

For air rejuvenation systems, SAMMS can provide a controlled release of the carbon dioxide using a gentle application of heat or vacuum, according to PNNL.

“The technology could open doors to other large-scale or small-scale air quality treatments,” Fryxell said.

Read the rest here:
PNNL honored for nanotechnology to help sailors

NEW YORK, May 16, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0181059/Global-Nanobiotechnology-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nanotechn

This report analyzes the worldwide markets for Nanobiotechnology in US$ Million by the following Technology Segments: Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, & Other Nanomaterials), and Nanodevices/Tools. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 117 companies including many key and niche players worldwide such as Aduro BioTech, Arrowhead Research Corporation, Calando Pharmaceuticals, Inc., Agilent Technologies Inc., Asklepios BioPharmaceutical Inc., Biosante Phosphate Pharmaceuticals, Inc., Celgene Corporation, Elan Pharmaceuticals, Elitech Group, Flamel Technologies, Inc., Gilead Sciences Inc., Life Technologies Corporation, NanoBio Corporation, Nanogen, Inc., Nanophase Technologies Corporation, pSivida Ltd., Sigma Aldrich Company, Starpharma Holdings Ltd., Dendritic Nanotechnologies, Inc., SkyePharma Pharmaceuticals, Unidym, Inc., and Zyvex Instruments LLC. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-3Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-31. Nanomaterials I-4Solid Inorganic Nanoparticles I-4Nanocomposites I-4Nanostructured Materials and Membranes I-4Nanotubes and Fullerenes I-4Other Nanomaterials I-4Nanoshells I-4Nanohorns I-5Nanocapsules I-52. Nanodevices/Tools I-5II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

A Curtain Raiser II-1

Nanobiotechnology – The Next Big Thing II-2

Nanotechnology & Biology Tie the Knot: “Two to Tango” II-4

Where Conventional Molecular Science Falls Short Nanobio

Steps In II-4

Visit link:
Global Nanobiotechnology Industry

Originally posted here:
Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine'

Public release date: 15-May-2012 [ | E-mail | Share ]

Contact: Dennis Tartaglia dtartaglia@tartagliacommunications.com 732-545-1848 Tartaglia Communications

MetLife Foundation today announced the recipients of its 2012 Awards for Medical Research in Alzheimer’s Disease: Clifford R. Jack Jr., M.D., professor of Radiology and The Alexander Family Professor of Alzheimer’s Disease Research at Mayo Clinic (Rochester, MN), and Christine Van Broeckhoven, Ph.D. D.Sc., professor and department director of the VIB Department of Molecular Genetics at the University of Antwerp (Belgium). In addition, Randall J. Bateman, M.D., associate professor of Neurology at the Washington University School of Medicine in St. Louis, is recipient of MetLife Foundation’s Promising Investigator Award.

Dr. Jack, an innovator in clinical studies of brain structure in disease, developed and applied imaging methodologies to determine and track the stages of Alzheimer’s disease. Dr. Van Broeckhoven, a basic scientist and expert in molecular genetics, has made groundbreaking discoveries establishing the genetic basis of inherited Alzheimer’s disease and related disorders. Dr. Bateman, a neurologist and biochemist, has pioneered the use of measurements of beta-amyloid protein in the brain to better understand the biochemical basis of this illness.

The winners were recognized at a scientific briefing and awards ceremony today in New York.

“MetLife Foundation is proud to present these awards that recognize outstanding achievements in medical research,” said Dennis White, president and chief executive officer, MetLife Foundation. “Doctors Jack, Van Broeckhoven and Bateman have made significant contributions to our understanding of Alzheimer’s disease and their dedication helps bring us closer to finding a cure for Alzheimer’s disease.”

About the Awards

Now in their 26th year, the awards provide outstanding researchers with an opportunity to freely pursue new ideas. At the heart of the program is a belief in research as the road to understanding and ultimately treating this devastating disease. Each major award recipient receives a $200,000 research grant for his or her institution to further their work, and a personal prize of $50,000. The recipient of the Promising Investigator Award receives a $100,000 grant to his institution to further his work in Alzheimer’s disease. MetLife Foundation established the awards in 1986 to recognize and reward scientists demonstrating significant contributions to the understanding of Alzheimer’s disease.

The MetLife Awards for Medical Research in Alzheimer’s Disease are managed by the American Federation for Aging Research (AFAR). Founded in 1981, AFAR has championed the cause and supported the funding of science in healthier aging and age-related medicine.

“We have selected these individuals because of their novel and significant approaches to Alzheimer’s disease, which are paving the way for additional discoveries that are important for diagnosis and treatments for this disease,” said Donald L. Price, M.D., chair of the MetLife Awards for Research in Alzheimer’s Disease Advisory Committee, which selected the winners. Dr. Price, professor of Pathology, Neurology and Neuroscience, Johns Hopkins School of Medicine, is a previous recipient of the MetLife Award.

Read more:
MetLife Foundation recognizes Alzheimer's disease research with prestigious awards

Public release date: 15-May-2012 [ | E-mail | Share ]

Contact: Zina Poletz zpoletz@webershandwick.com 612-719-2024 Weber Shandwick Worldwide

FORT KNOX, Ky., May 15, 2012 The U.S. Army Medical Department announced today the election of two of its own to Mastership in the American College of Physicians (MACP). Only 43 medical leaders from around the world who have achieved eminence through their contributions to the field of internal medicine in at least one area, such as practice, teaching, research or volunteerism, were awarded a Mastership in 2012. One of the Masters, Col. Gregory J. Argyros, M.D., MACP, who is board-certified in critical care medicine, pulmonology and internal medicine, is director of education, training and research for the Joint Task Force National Capital Region Medical, and professor of medicine at the Uniformed Services University of the Health Sciences. He previously served as chief of medicine and director of the internal medicine residency program at Walter Reed Army Medical Center, and as the ACP Army Chapter Governor from 2005-2009. In addition, Dr. Argyros has received numerous teaching awards over the years.

Recently retired as an Army colonel after a 27-year career, Alan J. Magill, M.D., MACP, was also honored as a Master by the College. Dr. Magill is currently a program manager at the Defense Advanced Research Projects Agency, where he develops effective interventions in the event of an influenza epidemic. He previously served as director of the Division of Experimental Therapeutics at the Walter Reed Army Institute of Research, and is an attending physician with the Infectious Disease Service at Walter Reed National Military Medical Center. He also teaches at the Uniformed Services University of the Health Sciences. Dr. Magill has held leadership positions in infectious disease at the National Institute of Health, International Society of Travel Medicine, American Society of Tropical Medicine and Hygiene, and other organizations.

“That two Army physicians were inducted as Masters by the American College of Physicians speaks to the high quality of physicians who choose to make the Army their career and the extraordinary opportunities Army medicine offers them,” said Col. Jeanne Tofferi, M.D., MPH, FACP, internal medicine consultant to the Army Surgeon General. “Both of them have made tremendous contributions to our nation through teaching, medical practice and research.”

On April 19, during the ACP annual meeting in New Orleans, six Army internal medicine physicians and subspecialists joined their Army ACP Chapter Governor, Col. Lisa Zacher, M.D., FACP, for a convocation ceremony during which they were inducted as Fellows of the American College of Physicians (FACP). These physicians included: Lt. Col. Michael G. Rossman, M.D. (Rheumatology), Daniel W. Franks, D.O. (Internal Medicine), Maj. Kimberly C. Salazar (Allergy/Immunology), Maj. Paige E. Waterman, M.D. (Infectious Disease), Anne B. Rossignol, M.D. (Hospice Care & Palliative Medicine) and Mark Garfinkle, M.D. (Internal Medicine).

Criteria for Fellowship include board certification by the American Board of Internal Medicine, recognition by other internists for excellence and skill in medical practice, teaching or research, and commitment to continued education and advanced training. Fellows of ACP are recommended by their peers based on character, ethics and excellence in medical practice, and undergo the review by ACP’s Credentials Subcommittee.

“The Army makes board certification and continuing medical education a top priority,” said Col. Zacher, who is also the pulmonary consultant to the Army surgeon general and chief, Department of Medicine, Brooke Army Medical Center. “The fact that so many Army physicians have become Fellows of the ACP speaks to their professional excellence in internal medicine and dedication to the highest quality of patient care.”

The following Army internists and subspecialists were elected as Fellows in 2012 (listed by Army medical center or affiliation):

Walter Reed National Military Medical Center (Washington, D.C.) Col. Ronald D. DeGuzman, M.D. (Allergy/Immunology); Maj. Fouad J. Moawad, M.D. (Gastroenterology); Maj. James E. Moon, M.D. (Internal Medicine); Maj. Kristopher M. Paolino, M.D. (Infectious Disease); Maj. Sheri K. Dennison, M.D. (Hematology/Oncology); Maj. Aaron B. Holley, M.D. (Pulmonology/Critical Care Medicine); Maj. Jeffrey S. Kunz, M.D. (Cardiology); Maj. Kevin M. Woods, M.D. (Cardiology); Maj. Ganesh Veerappan, M.D. (Gastroenterology); Lt. Col. Paige E. Waterman, M.D. (Infectious Disease ); Maj. Jason A. Regules, M.D. (Infectious Disease)

Originally posted here:
US Army internal medicine Masters, Fellows honored by American College of Physicians

ATLANTA, May 15, 2012 (GLOBE NEWSWIRE) — The Foundation for Mitochondrial Medicine, a US-based non-profit dedicated to funding research for the treatment of mitochondrial disease, has awarded a $10,000 grant to Dr. Robin Morris and his team of researchers at the Department of Psychology at Georgia State University for a joint research study at the Georgia State/Georgia Tech Joint Center for Advanced Brain Imaging. The research project will study brain function in 30 children with mitochondrial disease and in a control group of 30 children without mitochondrial disease using Functional Magnetic Resonance Imaging and other technology.

The aim of the study is to determine if children with oxidative phosphorylation (OXPHOS) defects in mitochondrial disease/dysfunction show indices of brain “fatigue” through testing by functional MRI (fMRI), diffusion tensor imagine (DTI) and neuropsychological testing. OXPHOS is a cellular metabolic process the body uses to turn oxidation of nutrients into energy.

The OXPHOS process uses approximately 95 percent of the oxygen delivered to tissues, and defects in this process can impact cellular energy functions throughout the body. While less than 2 percent of the adult human’s body weight, at rest the brain consumes about 20 percent of the oxygen, making the study of active brain function using techniques such as fMRI a useful approach for understanding the impact of OXPHOS defects.

The study is evaluating the concept of cognitive fatigue in these children, many of whom have difficulty maintaining the necessary mental focus and sustained attention over typical periods of activities and learning, which impacts their performance in school and other activities. The study is an essential step in being able to perform large-scale epidemiological studies of mitochondrial disease using more widely available measures, and ultimately being able to implement clinical trials for new pharmaceutical agents emerging for treatment of such defects.

There is already evidence that OXPHOS defects are associated with changes in the brain’s structure and function, and this study will integrate many types of information, including laboratory measures of OXPHOS defects, tests of neuropsychological functioning, measures of brain structure and function calibrated blood flow.

During the study, Dr. Morris and his team will conduct high-resolution anatomic brain scans to identify regions of interest for analyses of fMRI and diffusion tensor imaging (DTI) data to identify possible differences in white matter connectivity between the two groups of children (with and without OXPHOS). They will assess each child using thinking tasks that vary in degree of verbal working memory and sustained attention while undergoing functional MRI scans to evaluate changes in brain function over time.

The ultimate objective is to establish whether, and how, OXPHOS defects relate to the neurologic features of some children, causing rapid “cognitive fatigue.” Currently, such studies are difficult because definitive diagnosis of OXPHOS defects requires muscle biopsy and complex, unique genetic analyses.

The funding by the Foundation for Mitochondrial Medicine will enable Dr. Morris and his fellow researchers to study at least 10 participants in depth. Dr. Morris is a developmental neuropsychologist on the faculty in the Department of Psychology at Georgia State University and a licensed psychologist in the state of Georgia. He has an extensive history of studying children with both developmental and acquired neurological disorders, including studies of children with mitochondrial disease and autism. His fellow researcher Dr. Diana Robins has an extensive history of studying autism spectrum disorders and conducting fMRI studies, and Dr. Tricia King has been conducting fMRI and DTI studies with children and adults with a variety of acquired neurological disorders for many years as well.

The Foundation for Mitochondrial Medicine’s mission is to support the development of the most promising research and treatments of the many forms of mitochondrial disease. In addition to the current grant, the Foundation is currently funding drug compound research by Dr. Jan Smeitink of Khondrion in the Netherlands, and has funded an FDA-approved drug trial in 2010. Mitochondrial disease is an energy production problem that occurs when the cell’s mitochondria, or “power plants,” don’t function properly and create an energy crisis. The disease primarily affects brain, heart and muscle cells in varying degrees. More than 1 in 2,500 are affected by mitochondrial disease, and the treatments and cures for mitochondrial disease can impact cures for related diseases like Autism, Alzheimer’s, Parkinson’s, and muscular dystrophy among others. For more information on the Foundation and information about funding of specific research projects, please visit www.mitochondrialdiseases.org.

Media contacts: Foundation for Mitochondrial Medicine — Jennifer Grizzle, 770-409-1152, jennifer@theprstudio.com Georgia State University — Jeremy Craig, 404-413-1357, jcraig@gsu.edu Georgia Institute of Technology — Jason Maderer, 404.385.2966, maderer@gatech.edu

See the original post here:
Foundation for Mitochondrial Medicine Awards Grant to Functional MRI Study of Children With Mitochondrial Disease

Most medicine cabinets contain a jumble of over-the-counter health products, but knowing what to use, when, can be confusing. Just because a medication is sold without a prescription doesn’t mean it is harmless, and some old standbys can do more harm than good. Based on consultations with experts and reference materials, here is a deceptively easy quiz from The Wall Street Journal to test your home-remedy literacy.

1. You have a headache. Should you take: A) Advil (ibuprofen) B) Tylenol (acetaminophen) C) Aspirin

Answer: A, B or C

All of them will relieve a simple headache, but through different means and with different side effects.

Advil and Motrin (ibuprofen), Aleve (naproxen sodium) and aspirin all reduce pain by fighting inflammation, which also makes them particularly useful for combating arthritis, tooth pain, menstrual cramps and muscle sprains. But they can cause stomach bleeding, so people with peptic ulcers, liver, kidney or heart disease should talk to their doctors before taking them.

Aspirin has the added benefit of preventing blood clots, which is why taking one daily can lower the risk of cardiovascular disease. But aspirin shouldn’t be used by people who have low blood pressure or open wounds, or by children who have the flu or chickenpox due to the risk of Reye’s syndrome, a rare neurological disorder.

Tylenol (acetaminophen) works by calming pain signals in the brain. But it can cause liver damage if you regularly have three or more alcoholic drinks a day or take a higher dosage than recommended.

All in all, ibuprofen is arguably the strongest, but aspirin works faster, naproxen lasts longer and acetaminophen is safer if you have stomach problems (and aren’t a heavy drinker). A few brands contain both acetaminophen and aspirin, but don’t mix them on your own and don’t take any of them for more than five days straight, since they can cause “rebound” headaches, in which the body feels withdrawal when they wear off.

2. To clean a cut or scrape, it is best to use: A) Hydrogen peroxide B) Isopropyl (rubbing) alcohol C) Neither D) Both

Answer: C

Excerpt from:
The medicine cabinet quiz

www.youtube.com/watch?v=OhkwfZWM5TQ

Read the original here:
Wind River Optimizes its Intelligent Systems for 3rd Generation Intel® Core™ Processors – Video

aap Implantate AG, a medical technology company listed in the Frankfurt Stock Exchange`s Prime Standard segment, generated EUR9.9 million in sales (previous year: EUR6.5 million) in the first three months of financial year 2012, which was a 51% increase on the previous year`s first quarter. This strong sales growth was due mainly to an 18% increase in product sales to EUR7.7 million (previous year: EUR6.5 million) and to revenue from the conclusion of an exclusive license agreement worth EUR2.2 million with a world-leading medical technology company. EBITDA increased to EUR2.1million (previous year: EUR0.8 million).

*Full-Time-Equivalents (FTE) are the number of full-time employed persons during a period

In the first quarter of 2012 aap Group`s EBIT was EUR1.3million (previous year: EUR0.1 million) and its EBT amounted to EUR1.2 million (previous year: EUR0.1 million). On a balance sheet total of EUR67.1 million (31.12.2011: EUR63.4 million) the equity ratio was 74%.

In the first quarter, aap presented its innovative LOQTEQ product line to potential new distributors in Europe, the United States, Asia and Latin America, while the centre of excellence for trauma in Berlin continued to work on the FDA approval of the LOQTEQ product family. aap expects to receive full FDA approval on the LOQTEQ product line in the third quarter of 2012. The center of excellence for contract manufacturing in Nijmegen signed in the first quarter a contract to process human tissue with the Dutch Sanquin bone and tissue bank.

Outlook for 2012

On the basis of the positive result for the first quarter, the current order intake and potential new customer relationships, aap Implantate AG is revising its sales forecast for the financial year 2012. The Management Board now anticipates total sales of around EUR34 million (previous forecast: aroundEUR 32 million), or 16% sales growth on the previous year.

The main strategic focus in the financial year 2012 will be on the core business segments trauma and bone cement and cementing techniques, in which aap aims to achieve double-digit sales growth and a positive Cash-EBIT. Sales growth is to be realised through the launch of the innovative LOQTEQ product line and its FDA approval along with further strong sales growth in the bone cement and cementing techniques segment, license business, OEM contracts and another project deal.

aap Implantate AG`s full report for the first quarter of 2012 is available for you to download at www.aap.de.

This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap`s public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments. ______________________________________________________ aap Implantate AG (ISIN DE0005066609) – Prime Standard/Regulated Market – All German stock markets –

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company`s products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company`s products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap`s stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de.

View post:
aap reports profitable Q1 2012 sales growth of 51% to EUR 9.9 million; Increased sales forecast for the financial year …

Breakthrough by Irish scientists could spell end of needle jab

By Eoin English

Tuesday, May 15, 2012

Scientists based at an Irish research hub are developing medical technology which could spell the end of the dreaded needle jab.

Almost 180 clinicians, scientists and entrepreneurs from 25 countries are in Cork this week to discuss the future of microneedle technology at a conference hosted by the Tyndall National Institute and UCC.

Microneedles, which consist of tiny spikes just 0.1mm to 1.0mm in length, are made using techniques adapted from the computer chip industry.

Arrays of microneedles will be worn like a plaster or skin patch, where they will penetrate the skin and release a drug or vaccine into the body.

They will be used to treat conditions ranging from diabetes to osteoporosis, and will play a major role in low-cost public health management activities such as the annual flu vaccination programme.

But crucially, because they are microscopic, they are completely painless to wear, and users will no longer need to attend a doctors surgery for needle-based injections.

Experts reckon the devices will be on the market within just a few years, capturing a slice of a $30bn (23.36bn) medical market.

Visit link:
Breakthrough by Irish scientists could spell end of needle jab

RICHLAND, Wash.–(BUSINESS WIRE)–

IsoRay Inc. (AMEX: ISR – News), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced its financial results for the third fiscal quarter ended March 31, 2012.

IsoRay Chairman and CEO Dwight Babcock commented, “Our quarterly financial performance, while flat, reflects the building of inventory and marketing efforts aimed at growing product awareness in anticipation of the launch of our GliaSite radiation therapy system and lung cancer mesh sales internationally. Our revenues from sales for the treatment of other body sites beyond the prostate grew 27% comparing the nine months ended March 31, 2012 to the nine months ended March 31, 2011. We also saw growth in the number of physicians and facilities ordering cases for non-prostate body sites. The number of physicians ordering grew 57% and the number of facilities ordering grew 60% year to date respectively.”

The GliaSite radiation therapy system is the world’s only balloon catheter device used in the treatment of brain cancer, and is being reintroduced to the market by IsoRay, which has exclusive worldwide rights to the system. IsoRay is also the exclusive manufacturer of Cesium-131, which represents one of the most important advancements in internal radiation therapy in 20 years. Cesium-131 allows for the internal radiation treatment of many different cancers because of its peerless combination of high energy and its matchless speed in giving off therapeutic radiation (9.7 day half-life).

IsoRay has taken some significant steps forward during the quarter. A growing number of institutions, including John Hopkins Hospital, Columbia University Medical Center, Baylor and others, are seeking amendments to their state radiation licenses. Typically, a license amendment is a 2 to 4 month process which allows institutions, upon approval, to make IsoRay’s products available for patient treatment.

In recent weeks, the Company participated in the 80th Annual Meeting of the American Association of Neurological Surgeons (AANS) marking the Company’s formal introduction to the neuroscience community. During the meeting, a number of thought leaders in the medical community spoke about their experiences with the GliaSite radiation therapy system. At the meeting, one physician reported historical results with GliaSite in treating his last surviving patient with metastasized brain cancer. This metastasized brain cancer patient experienced an extraordinary 6 year extension of life with improved quality of life.

IsoRay also participated in the World Congress of Brachytherapy in Barcelona, Spain where the Company reintroduced the GliaSite brain cancer treatment and introduced its Cesium-131 lung cancer mesh to the international community. At the meeting, the Company met with 10 international distributors from a variety of countries who are seeking international distribution agreements for IsoRay’s products. IsoRay CEO Babcock says the Company is currently engaged in due diligence to evaluate whether to proceed with negotiations with those companies.

Also at that meeting, a number of studies, as published in the Brachytherapy Journal of the ABS, were presented spotlighting crucial findings regarding Cesium-131 brachytherapy. New York Presbyterian Radiation Oncologist Dr. A. Gabriella Wernicke, M.D., M.Sc., presented a paper reporting on the successful results New York-Presbyterian/Weill Cornell Medical Center doctors have achieved using sutured Cesium-131 seeds to treat metastasized brain cancer. Dr. Bhupesh Parashar, Radiation Oncologist at New York-Presbyterian/Weill Cornell Medical Center, presented an initial report of outcomes relative to toxicity and radiation exposure in the use of Cesium-131 brachytherapy for head and neck cancers. The report concludes that Cesium-131 brachytherapy is a safe and effective option for high risk head and neck cancers, producing high control rates, limited toxicity and is safe for health personnel in terms of radiation exposure. In addition, UPMC radiation oncologist and associate professor of radiation oncology Dr. Sushil Beriwal reported on long term toxicity following Cs-131 prostate brachytherapy. Dr. Beriwal and his colleagues found most patients undergoing prostate brachytherapy with Cs-131 have no urinary or bowel toxicity at the three year post-brachytherapy mark. Dr. Beriwal also presented a paper which investigated whether there is a difference in PSA spikes using Cesium-131 brachytherapy as opposed to other radioisotopes. While Cesium-131 treats cancer more aggressively, the report states that it has no different long term PSA spike effect than other radioisotopes. In addition, Dr. Deepak Khuntia, Director of Research and Education for Western Radiology Oncology in California, was a speaker on Robot Assisted Mesh Brachytherapy after Sublobar Resection for Early Stage Lung Cancer. In comments following his presentation, Dr. Khuntia cited several advantages in the use of Cesium-131 in robot assisted mesh brachytherapy treatment over radioisotope I-125.

Net loss applicable to common shareholders

Weighted average shares used in computing net loss per share:

See the article here:
IsoRay, Inc. Reports Third Quarter Results

Continued here:
St Jude is latest to launch blood pressure device

CHARLOTTE, N.C.–(BUSINESS WIRE)–

Camstar Systems, Inc. announced today an agreement to deploy its Camstar Enterprise Platform for medical device manufacturer Stryker, a leading medical technology company that helps healthcare professionals perform their jobs more efficiently while enhancing patient care.

Stryker is dedicated to offering top quality products and services that provide enduring value to medical professionals and patients, said Brian Rieck, program director, IT integration for Stryker. The Camstar solution gives us great control over our manufacturing processes and allows us to streamline and lock down critical steps to ensure the process works as intended, every time.

Stryker joins other leading global manufacturers that place the highest importance on patient safety and understand the strategic value of standardizing on Camstars Enterprise Platform, said Rob Rudder, executive vice president for Camstar. Camstars clear leadership and investment in the medical device manufacturing industry are making a difference to this important industry.

About Stryker

Stryker is one of the worlds leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives.

For more information, please visit www.stryker.com.

About Camstar Systems, Inc.

Camstar is a leading innovator of software solutions that advance product quality in the manufacturing industry, enabling Brand Owners, Manufacturers and Suppliers to produce the highest quality products through Global Supply Networks. Camstars cloud-based and on-premise solutions provide Supply Chain Visibility and Intelligence, Quality Management and Collaboration, and Manufacturing Execution.

For nearly 30 years, Camstar has servedhundreds of satisfied customers worldwide. For more information, please visit www.camstar.com.

Follow this link:
Stryker Deploys Camstar to Enable Growth, Efficiency and Top Product Quality

Published on May 16, 2012 at 2:16 AM

HyperBranch Medical Technology, Inc. announced today that it has received CE Marking for AdherusTM AutoSpray Dural Sealant. Adherus AutoSpray is a novel delivery system used for the delivery of HyperBranch’s dural sealant which is used in cranial and spine surgeries to prevent cerebrospinal fluid leaks following the dural repair. Prevention of cerebrospinal fluid leaks should benefit the patient in fewer post-surgical complications such as leaks and infection thereby resulting in shorter hospital stays. The CE Mark provides regulatory approval for the company to begin sales in countries outside the U.S.

“Adherus AutoSpray is the first self-contained bioadhesive spray applicator that eliminates cumbersome preparation steps for the scrub nurse and allows the surgeon to effortlessly and precisely start and stop dispensing without concern for clogging. It complements the Company’s other neurosurgery products: AdherusTM Dural Sealant and AdherusTM MIS. All the Company’s products share the same proprietary chemistry that provides controlled performance while degrading slowly during the healing process. It not only provides a watertight seal but acts as an adhesion barrier to limit scarring, a major advantage if subsequent surgery is required,” said John Conn, President and Chief Executive Officer.

The AdherusTM products are synthetic hydrogels which polymerize in a moist field, flow optimally depending on the application, and biodegrade as the tissue heals.

HyperBranch Medical Technology, Inc. has now received CE Marks for five of their products. The Company has completed a U.S. feasibility study and is nearing completion of the Pivotal portion for its cranial product which includes the new AutoSpray device. An FDA IDE for the MIS device has also been approved and will follow the same approval path in the U.S. as the AutoSpray.

Source: HyperBranch Medical Technology

View post:
HyperBranch’s Adherus AutoSpray Dural Sealant receives CE Marking